EyePoint Pharmaceuticals Statistics
Total Valuation
EYPT has a market cap or net worth of $758.89 million. The enterprise value is $526.87 million.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EYPT has 68.93 million shares outstanding. The number of shares has increased by 38.62% in one year.
| Current Share Class | 68.93M |
| Shares Outstanding | 68.93M |
| Shares Change (YoY) | +38.62% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 72.29% |
| Float | 42.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.72 |
| Forward PS | 61.97 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.00, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.00 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13,503.64 |
Financial Efficiency
Return on equity (ROE) is -73.95% and return on invested capital (ROIC) is -45.33%.
| Return on Equity (ROE) | -73.95% |
| Return on Assets (ROA) | -37.79% |
| Return on Invested Capital (ROIC) | -45.33% |
| Return on Capital Employed (ROCE) | -70.55% |
| Revenue Per Employee | $314,533 |
| Profits Per Employee | -$1.06M |
| Employee Count | 165 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 58.46 |
Taxes
In the past 12 months, EYPT has paid $183,000 in taxes.
| Income Tax | 183,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.70% in the last 52 weeks. The beta is 1.75, so EYPT's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | +31.70% |
| 50-Day Moving Average | 9.76 |
| 200-Day Moving Average | 8.00 |
| Relative Strength Index (RSI) | 61.86 |
| Average Volume (20 Days) | 610,839 |
Short Selling Information
The latest short interest is 6.91 million, so 10.03% of the outstanding shares have been sold short.
| Short Interest | 6.91M |
| Short Previous Month | 6.72M |
| Short % of Shares Out | 10.03% |
| Short % of Float | 16.21% |
| Short Ratio (days to cover) | 10.81 |
Income Statement
In the last 12 months, EYPT had revenue of $51.90 million and -$175.38 million in losses. Loss per share was -$2.71.
| Revenue | 51.90M |
| Gross Profit | -133.71M |
| Operating Income | -189.05M |
| Pretax Income | -86.74M |
| Net Income | -175.38M |
| EBITDA | -187.14M |
| EBIT | -189.05M |
| Loss Per Share | -$2.71 |
Full Income StatementBalance Sheet
The company has $255.73 million in cash and $23.72 million in debt, giving a net cash position of $232.02 million or $3.37 per share.
| Cash & Cash Equivalents | 255.73M |
| Total Debt | 23.72M |
| Net Cash | 232.02M |
| Net Cash Per Share | $3.37 |
| Equity (Book Value) | 246.01M |
| Book Value Per Share | 3.57 |
| Working Capital | 232.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.59 million and capital expenditures -$3.45 million, giving a free cash flow of -$194.04 million.
| Operating Cash Flow | -190.59M |
| Capital Expenditures | -3.45M |
| Free Cash Flow | -194.04M |
| FCF Per Share | -$2.82 |
Full Cash Flow StatementMargins
| Gross Margin | -257.63% |
| Operating Margin | -364.27% |
| Pretax Margin | -337.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EYPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.62% |
| Shareholder Yield | -38.62% |
| Earnings Yield | -23.11% |
| FCF Yield | -25.57% |
Analyst Forecast
The average price target for EYPT is $24.88, which is 125.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.88 |
| Price Target Difference | 125.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 62.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 0 |
| Piotroski F-Score | 1 |